Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07270016

Pilot-Testing Real-Time Engagement for Learning to Effectively Control Type 2 Diabetes

The goal of this study is to pilot test features of a new smartphone app and to gather feedback related to wearing a continuous glucose monitor (CGM) and a Fitbit device, as well as to obtain input on health behavior-focused messages delivered through the app. The study will enroll English-speaking participants aged 16-24 years who were diagnosed with type 2 diabetes before age 18. Participants will be asked to fill out surveys about diabetes, physical activity, and diet before and after wearing a CGM for 30 days. At the end of wearing the CGM, participants will complete an interview about their experience.

Recruiting

Interested in participating?

Request Info

Key information

Age range

16 year–24 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ages 16-24 years, any sex or gender
  • Diagnosis of type 2 diabetes in childhood (younger than 18 years of age)
  • English-speaking (app in English)
  • Possession of personal smartphone that is compatible with FreeStyle Libre app

Exclusion criteria

  • Cognitive impairment or severe psychiatric conditions that could interfere with participation in behavioral intervention for diabetes self-management

Treatment and study plan

Healthmine app

Other

Participants will wear study-provided continuous glucose monitoring device and Fitbit physical activity tracker for 30 consecutive days. During the same period, they will use an investigator-developed smartphone app (Healthmine), which is being developed to pair CGM and Fitbit data. Participants will receive up to one message about health behavior change (e.g., physical activity, nutrition) daily and will be able to use Healthmine to log exercise and dietary intake.

Primary outcomes

  1. Usability of Healthmine app

    Time frame: 15 days and 30 days after starting study-provided CGM and Healthmine app use

    Assessed via the System Usability Scale (SUS), a 10-item questionnaire measuring perceived usability of a system or technology. Each item is rated on a 5-point Likert scale ranging from 1 ("strongly disagree") to 5 ("strongly agree"). The total SUS score is calculated by summing the score contributions from each item (for odd-numbered items, subtract 1 from the user response; for even-numbered items, subtract the user response from 5), multiplying the sum by 2.5, resulting in a score ranging from 0 to 100. Higher scores indicate better perceived usability, with scores above 68 considered above average usability.

Secondary outcomes

  1. Days with CGM data

    Time frame: 30-day CGM wear period

    The number of days with continuous glucose monitoring data available will be divided by the total number of requested days of wear (30) to obtain percentage of days with data.

  2. Days with Fitbit data

    Time frame: 30-day Fitbit wear period

    The number of days with Fitbit data available will be divided by the total number of requested days of wear (30) to obtain percentage of days with data.

  3. Mean CGM glucose

    Time frame: 30-day CGM wear period

    Mean glucose obtained from study-provided CGM

  4. Step count

    Time frame: 30-day Fitbit wear period

    Step count data will be obtained via study-provided Fitbit.

  5. Diabetes Self-Management

    Time frame: Baseline and 30 days (change from baseline to 30 days)

    Assessed via the Diabetes Self-Management Questionnaire (DSMQ), a 16-item self-report questionnaire measuring diabetes self-care activities associated with glycemic control. Each item is rated on a 4-point Likert scale (0 = "does not apply to me" to 3 = "applies to me very much"). Items are summed (after reverse-coding negatively worded items) and transformed to a 0-10 scale, where higher scores indicate better self-management.

  6. Treatment Self-Regulation

    Time frame: Baseline and 30 days (change from baseline to 30 days)

    Assessed via the Treatment Self-Regulation Questionnaire (TSRQ), a questionnaire measuring the degree to which a person's motivation for health behaviors is relatively autonomous (self-determined) versus controlled (motivated by external factors). Items are rated on a 7-point Likert scale (1 = "not at all true" to 7 = "very true"). The TSRQ yields subscale scores for autonomous regulation, controlled regulation, and amotivation, with higher scores on each subscale indicating greater levels of that type of motivation.

  7. Self-Reported Physical Activity

    Time frame: Baseline and 30 days (change from baseline to 30 days)

    Assessed via the PACE+ Physical Activity Measure, a brief self-report questionnaire measuring physical activity levels. Participants report the number of days per week they engage in moderate or vigorous physical activity for at least 30 minutes (or 60 minutes for adolescents). The measure yields separate scores for moderate and vigorous activity (each ranging from 0-7 days per week), with higher scores indicating greater physical activity frequency.

  8. Diet Quality

    Time frame: Baseline and 30 days (change from baseline to 30 days)

    Assessed via the Prime Diet Quality Score (PDQS), a food-based dietary assessment tool that evaluates diet quality across 15 food group components. The PDQS includes 10 adequacy components (dark green leafy vegetables, cruciferous vegetables, carrots, other vegetables, citrus fruits, other fruits, fish/seafood, eggs, whole grains, and low-fat dairy) and 5 moderation components (red meat as main dish, processed meat, refined grains and baked goods, sugar-sweetened beverages, and fried foods). Each component is scored based on consumption frequency, with higher scores indicating greater intake of health-promoting foods and lower intake of foods that should be consumed in moderation. The total PDQS ranges from 0-30, with higher scores indicating better overall diet quality.

  9. Glucose monitoring satisfaction

    Time frame: 30 days (following CGM wear period)

    Assessed via the Glucose Monitoring Satisfaction Survey (GMSS) for Type 2 Diabetes, a 15-item questionnaire measuring patient satisfaction with their glucose monitoring device. Items are rated on a 5-point Likert scale (1 = "strongly disagree" to 5 = "strongly agree"). The GMSS yields four subscale scores: Openness (items 1, 8, 10, 14), Emotional Burden (items 2, 5, 9, 13), Behavioral Burden (items 3, 6, 11, 15), and Worthwhileness (items 4, 7 [reverse coded], 12). Subscale scores are calculated as the mean of item responses, with higher scores indicating greater openness, greater burden (for burden subscales), and greater worthwhileness, respectively. A total satisfaction score is calculated as the mean of all items after reverse-coding items 2, 3, 5, 6, 7, 9, 11, 13, and 15, with higher total scores indicating greater overall satisfaction with glucose monitoring.

  10. Glucose coefficient of variation

    Time frame: 30-day CGM wear period

    Based on CGM glucoses, coefficient of variation will be calculated by dividing the standard deviation of glucose readings by the mean glucose level, then multiplying by 100 to get a percentage.

  11. Glucose time below range

    Time frame: 30-day CGM wear period

    Percent of time with CGM glucose less than 70 mg/dL

  12. Glucose time in range

    Time frame: 30-day CGM wear period

    Percent of time with CGM glucose 70-180 mg/dL

  13. Glucose time above range

    Time frame: 30-day CGM wear period

    Percent of time with CGM glucose above 180 mg/dL

  14. Mean amplitude of glycemic excursions

    Time frame: 30-day CGM wear period

    A measure of glucose variability calculated from CGM data, calculated by dividing the standard deviation of glucose readings by the mean glucose level, then multiplying by 100 to get a percentage.

Study contacts

Contact information is provided by the study sponsor or research team.

Mary Ellen Vajravelu, MD, MSHP

CONTACT

[email protected]

4126926533

Sponsors and collaborators

Lead sponsor

University of Pittsburgh

Other

Collaborators

  • Dartmouth College
  • Emory University
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • San Diego State University
  • University of Michigan

Registry information

Official study title

Real-Time Engagement for Learning to Effectively Control Type 2 Diabetes: Pilot Study

Acronym: REFLECT2DPilot

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Dec 8, 2025
Registry last updated
Feb 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.